2′-halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists
AssigneeLek Pharmaceuticals D.D.
InventorsAnton Copar, Zdenko Casar, Andrej Premrl
Life of this patent
Estimating the term…
Loading patent…
AssigneeLek Pharmaceuticals D.D.
InventorsAnton Copar, Zdenko Casar, Andrej Premrl
Estimating the term…
A process for obtaining 2′-halo-4-methylbiphenyls is described, which comprises reacting 4 halotoluene with a 1,2-dihalobenzene in the presence of elemental metal such as magnesium, lithium or zinc, wherein 0 to 0.9 molar, particularly 0 to 0.2 molar excess of 4-halotoluene in regard to 1,2-dihalobenzene is used, and arised organometal intermediates are quenched by elemental mental halogen. In addition, the coupling of arised 2′-halo-4-methylbiphenyls with 2-(1-propyl)-4-methyl-6-(1′-methylbenzimidazole-2-il)benzimidazole to afford 3′-(2′-halo-biphenyl-4-ylmethyl)-1,7′-dimethyl-2′-propyl-1H,3′H-[2,5′]bibenzoimidazolyl, which can be further converted to organometallic compound and said organometallic compound is further reacted with formic acid derivative, such as N,N-dimethylformamide, alkylformiate or carbon dioxide to obtain telmisartan, is also described. Further described is use of in line analytics for monitoring the aforementioned reactions, process for preparing a pharmaceutical composition and/or dosage for, or use in preparing a medicament.
A process for obtaining telmisartan or salt thereof, comprising converting 3′-(2′-halo-biphenyl-4-ylmethyl)-1,7′-dimethyl-2′-propyl-1H,3′H-[2,5′]bibenzoimidazolyl to an organometallic compound, reacting said organometallic compound with carbon dioxide to form telmisartan, or reacting said organometallic compound with formic acid ester or amide forming a telmisartan aldehyde precursor, and oxidizing said telmisartan aldehyde precursor to form telmisartan.
Dependencies are inferred from the claim text.
From the US filing history. Foreign family members aren’t listed.
No references of this kind are recorded.
By reactions involving an increase in the number of carbon atoms in the skeleton: by condensation reactions
Drugs for disorders of the cardiovascular system: antihypertensives
Of hydrogen atoms: in the side-chain of aromatic compounds
By condensation reactions: involving an organo-magnesium compound, e.g. Grignard synthesis
About 2 years 5 months of term left · ends 1 Apr 2029 (estimated)
This is a National Stage entry of International Application No. PCT/EP2009/053267, filed Mar. 19, 2009, the contents of the prior application are hereby incorporated herein in their entirety by reference.
The present invention relates in general to the field of organic chemistry and in particular to the preparation of substituted biphenyls, in particular to 4-halomethyl-2′-halobiphenyl and their use as intermediates in preparation of angiotensin II antagonists. The invention also relates to halo and organometal intermediates for preparing telmisartan. Further the invention relates to use of in line analytics. In addition, the invention relates to the process for preparing pharmaceutical composition and/or dosage form comprising the process for preparing said biphenyls or intermediates. The embodiments of the present invention can be beneficially applied also for preparing a medicament.
Angiotensin II antagonists (“sartans”) are efficient active compounds with biological activity which has proved useful for the treatment of hypertension. Most of commercially available sartans contain biphenyl moiety substituted with 5-tetrazolyl or carboxy group on the position 2′ (Formula 1, X is COOH or 5-tetrazolyl).
Surprisingly it has been found that 2′-halo-4-methylbiphenyls can be obtained in a simple one-pot two-step technical process, in yields that are industrially applicable and competitive in which a 4-halotoluene is reacted with a 1,2-dihalobenzene in the presence of magnesium, lithium, zinc, cobalt or copper, and optionally a catalyst selected from a transition metal compound, preferably a manganese, cobalt or copper compound, wherein less than 1, particularly less than 0.9 molar, particularly less than 0.2 molar excess of 4-halotoluene with regard to 1,2-dihalobenzene is used, that for each mol of 1,2-dihalobenzene, from 1.0 to 1.9, particularly from 1.0 to 1.2 mol 4-halotoluene is used, more particularly from 1.05 to 1.15 mol, and arisen organometal intermediates are quenched proportionally for each 1 mol of 1,2-dihalobenzene by less than 2.9 mol, particularly 1-2 mol, about 1 mol of elemental halogen.
The catalyst optionally used can be a palladium, copper, manganese, ruthenium, chromium, nickel compound, or the like.
Suprisingly it was noted that when the molar excess of 4-halotoluene with regard to 1,2-dihalobenzene is less than 1, preferably less than 0.9, more preferably less than 0.2, it significantly improves the reaction yield. The reason might be that the organometal reaction is a complex reaction and its yield depends on the ratio of reactants. In the case of the prior art ratio, when it was for 1,2-dihalobenzene to 4-halotoluene 1:2, the high excess of starting reactants like 4-halotoluene could induce transmetalation. Metalated 1,2-dihalobenzene could produce symmetric dimeric products in one side while liberated 4-halotoluene could consume more metal or produce symmetric dimeric products with prepared 4-metalated toluene on the other side. Such side reaction may considerably reduce yield and quality. Thus, reducing the molar excess of the 4-halotoluene in the metalo reaction surprisingly improved utility of the reaction in the industry. Further, it was unexpectedly observed that less halogen is needed to sufficiently quench the reaction, when the ratio of the starting reagents is changed.
Drawings are temporarily unavailable. Open the PDF at USPTO